	US 12,319,913 B2
	5-halouracil-modified microRNAs and their use in the treatment of cancer
Jingfang Ju, East Setauket, NY (US); Andrew Fesler, Sound Beach, NY (US); Younghwa Song, Port Jefferson Station, NY (US); and Jun Chung, Setauket, NY (US)
Assigned to The Research Foundation for The State University of New York, Albany, NY (US)
Filed by The Research Foundation for The State University of New York, Albany, NY (US)
Filed on Nov. 24, 2021, as Appl. No. 17/534,520.
Application 17/534,520 is a division of application No. 16/912,932, filed on Jun. 26, 2020, granted, now 11,236,337.
Application 16/912,932 is a continuation in part of application No. 16/176,137, filed on Oct. 31, 2018, granted, now 11,584,932.
Prior Publication US 2022/0090076 A1, Mar. 24, 2022
Int. Cl. C07H 21/02 (2006.01); A61P 35/04 (2006.01); C12N 15/113 (2010.01); A61K 9/00 (2006.01)

CPC C12N 15/113 (2013.01) [A61P 35/04 (2018.01); A61K 9/0019 (2013.01); C12N 2310/141 (2013.01); C12N 2310/335 (2013.01)]

5 Claims

1. A double-stranded modified microRNA nucleic acid composition for treating a triple negative breast cancer comprising a modified nucleotide sequence having uracil nucleic acids, wherein all the uracil nucleic acids including the seed region of the modified microRNA nucleotide sequence are 5-fluorouracils which is complementary to a portion of a MDC1 3′UTR nucleotide sequence or to a portion of a SUZ12 3′ UTR nucleotide sequence, to increase the potency of the modified microRNA nucleic acid composition in inhibiting cancer progression compared to 5-fluorouracil alone or a combination of 5-fluorouracil and a native microRNA, and the modified microRNA nucleotide sequence is CGACGGCAU^FAU^FACACU^FACAGU^FG [SEQ ID NO. 32] and wherein the modified microRNA nucleic acid binds to the complementary portion of the MDC1 3′UTR nucleotide sequence set forth in SEQ ID NO: 33 or the complementary portion of the SUZ12 3′ UTR nucleotide sequence set forth in SEQ ID NO 34.